Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adir Shaulov

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Annals of Hematology|March 21, 2020
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry studyYael C Cohen, Hila Magen, Noa Lavi, et al.
European Journal of Haematology|April 25, 2023
Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortalityShlomzion Aumann, Uria Tsubary, Boaz Nachmias, et al.
Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.
Leukemia Research|June 2, 2019
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemiaTamar Tadmor, Ilana Levy, Yair Herishanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL AmyloidosisShlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, et al.
Leukemia & Lymphoma|May 2, 2022
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphomaEyal Lebel, Neta Goldschmidt, Tali Siegal, et al.
Leukemia Research|January 16, 2021
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre studyTamir Shragai, Moshe E Gatt, Adir Shaulov, et al.
Palliative Medicine|March 25, 2021
Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapyLiza Barki-Harrington, Orna Baron-Epel, Adir Shaulov, et al.
Cancers|July 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?Vladimir Vainstein, Batia Avni, Sigal Grisariu, et al.
American Journal of Hematology|February 13, 2020
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working groupEirini Katodritou, Efstathios Kastritis, Moshe Gatt, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Annals of Hematology|March 21, 2020
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry studyYael C Cohen, Hila Magen, Noa Lavi, et al.
European Journal of Haematology|April 25, 2023
Risk factors and outcomes of COVID-19 in adult patients with hematological malignancies: A single-center study showing lower than expected rates of hospitalization and mortalityShlomzion Aumann, Uria Tsubary, Boaz Nachmias, et al.
Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.
Leukemia Research|June 2, 2019
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemiaTamar Tadmor, Ilana Levy, Yair Herishanu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL AmyloidosisShlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, et al.
Leukemia & Lymphoma|May 2, 2022
Rituximab, methotrexate, procarbazine and lomustine (R-MPL) for the treatment of primary Central nervous system lymphomaEyal Lebel, Neta Goldschmidt, Tali Siegal, et al.
Leukemia Research|January 16, 2021
Characteristics and outcome of multiple myeloma patients presenting with anaemia only: A retrospective multi-centre studyTamir Shragai, Moshe E Gatt, Adir Shaulov, et al.
Palliative Medicine|March 25, 2021
Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapyLiza Barki-Harrington, Orna Baron-Epel, Adir Shaulov, et al.
Cancers|July 14, 2023
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?Vladimir Vainstein, Batia Avni, Sigal Grisariu, et al.
American Journal of Hematology|February 13, 2020
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working groupEirini Katodritou, Efstathios Kastritis, Moshe Gatt, et al.
Pageof 6